NCT01703078View on ClinicalTrials.gov

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Actinic Keratosis
Interventions
DRUG

Ingenol once daily for two consecutive days

Trial Locations (1)

4102

Dermatology Department, Woolloongabba

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY